Document is current
Any future updates will be listed below
-
Authors
Esai Selvan, Myvizhi
Onel, Kenan
Gnjatic, Sacha https://orcid.org/0000-0001-5643-9520
Klein, Robert J. https://orcid.org/0000-0003-3539-5391
Gümüş, Zeynep H. https://orcid.org/0000-0002-7364-2202
-
Funding
Funding for this research was provided by:
LUNGevity Foundation
U.S. Department of Health & Human Services | National Institutes of Health (R33 CA263705-01, U24 CA224319, U01 DK124165, R01 CA167824)
Uniting Against Lung Cancer
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 15 July 2022
Accepted: 16 January 2023
First Online: 27 January 2023
Competing interests
: S.G. reports consultancy and/or advisory roles for Merck and OncoMed and research funding from Bristol-Myers Squibb, Genentech, Celgene, Janssen R&D, Takeda, and Regeneron. Other authors declare no competing interests.
